All listings for this product
Best-selling in Textbooks
Save on Textbooks
- AU $79.67Trending at AU $96.35
- AU $72.90Trending at AU $74.37
- AU $35.43Trending at AU $40.71
- AU $74.90Trending at AU $79.35
- AU $19.16Trending at AU $24.44
- AU $30.00Trending at AU $49.03
- AU $16.98Trending at AU $18.30
About this product
- DescriptionUntil the 1990s, it was generally accepted that medicines were first developed for adults and their use in children was investigated later, if at all. One of the main tasks of hospital pharmacies was the manufacturing of child-appropriate formulations in a more or less makeshift way. The first change came in 1997 with U.S. legislation that rewarded manufacturers to do voluntary pediatric research. Ten years later, the European Union passed legislation that required manufacturers to discuss all pediatric aspects, including formulations, with the regulatory authorities as a condition of starting the registration procedure. In consequence, manufacturers must w cover all age groups, including the youngest ones. So far, pediatric formulations were more a focus for academic researchers. Through the changed regulatory environment, there is w a sudden high commercial demand for age-appropriate formulations. This book begins by highlighting the anatomical, physiological and developmental differences between adults and children of different ages. It goes on to review the existing techlogies and attempts to draw a roadmap to better, invative formulations, in particular for oral administration. The regulatory, clinical, ethical and pharmaceutical framework is also addressed.
- Author BiographyDaniel Bar-Shalom is an Associate Professor in Drug Delivery at The Faculty of Health and Medical Sciences, University of Copenhagen. He has a degree in Biology from The Tel-Aviv University (1975), carried research in botany and then graduated from the School of Pharmacy, Hebrew University of Jerusalem (1982). He is a qualified pharmacist and has managed and owned a pharmacy in Haifa where he gained insight into the needs and idiosyncrasies of patients. He moved to Denmark in 1986 and founded Egalet, a drug delivery company where he served until 2007 as Vice President, R&D. He has been a consultant for various pharmaceutical and medical device companies. He is also the inventor of various technologies, holds many patents and has formulated marketed products. His main interests are controlled drug delivery and in particular oral pediatric formulations and geriatric formulations addressing the problem of polypharmacy. Dr. Klaus Rose is CEO of Klausrose Consulting, Switzerland and advises on pediatric drug development and how to comply with FDA and EMA pediatric requirements. He has studied Latin languages, psychology and medicine. After postgraduate clinical training in general medicine in Germany and England, he joined the pharmaceutical industry. He has held various positions in R&D and medical affairs, was Global Head Pediatrics Novartis from 2001 to 2005 and was Global Head Pediatrics Roche from 2005 to 2009. After a year with a regulatory consultancy, he established his own business. Dr. Rose is a frequent speaker on international conferences on pediatric drug development, organizes trainings and publishes on a regular base.
- PublisherSpringer-Verlag New York Inc.
- Date of Publication19/08/2016
- SubjectMedical Nursing & Ancillary Services
- Series TitleAAPS Advances in the Pharmaceutical Sciences Series
- Series Part/Volume Number11
- Place of PublicationNew York
- Country of PublicationUnited States
- ImprintSpringer-Verlag New York Inc.
- Content Note40 black & white illustrations, 36 colour illustrations, 28 black & white tables, biography
- Weight694 g
- Width155 mm
- Height235 mm
- Spine23 mm
- Edited byDaniel Bar-Shalom,Klaus Rose
- Edition StatementSoftcover reprint of the original 1st ed. 2014
This item doesn't belong on this page.
Thanks, we'll look into this.